Diseases [C] » Nervous System Diseases [C10] » Autoimmune Diseases of the Nervous System » Demyelinating Autoimmune Diseases, CNS » Multiple Sclerosis » Multiple Sclerosis, Relapsing-Remitting
Diseases [C] » Nervous System Diseases [C10] » Demyelinating Diseases » Demyelinating Autoimmune Diseases, CNS » Multiple Sclerosis » Multiple Sclerosis, Relapsing-Remitting
Diseases [C] » Immune System Diseases [C20] » Autoimmune Diseases » Autoimmune Diseases of the Nervous System » Demyelinating Autoimmune Diseases, CNS » Multiple Sclerosis » Multiple Sclerosis, Relapsing-Remitting
Description
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914) MeSH
Hierarchy View
Approved Indicated Drugs (6)
Phase 4 Indicated Drugs (31)
Phase 3 Indicated Drugs (30)
23-valent pneumococcal polysaccharide vaccine (pneumovax-23)
acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
Phase 2 Indicated Drugs (53)
Phase 1 Indicated Drugs (19)
Other Experimental Indicated Drugs (8)
Organization Involved with Phase 4 Indications (41)
Adolphe Rothschild Ophtalmologic Foundation
Amphia Hospital Breda, the Netherlands
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Organization Involved with Phase 3 Indications (63)
Alabama Neurology Associates, PC
Anne Arundel Health System Research Institute
Hospital of Central Denmark Region, Viborg, Denmark
Hospital of South West Jutland
Icahn School of Medicine at Mount Sinai
National Institute of Neurological Disorders and Stroke (NINDS)
Norwegian University of Science and Technology
Oregon Health and Science University
Russian State Medical University
The Multiple Sclerosis National Competence Centre
The Norwegian Multiple sclerosis Society
Organization Involved with Phase 2 Indications (86)
Advancell - Advanced In Vitro Cell Technologies, S.A.
Alberta Innovates Health Solutions
Badalona Hospital Germans Trias i Pujol
Buffalo Neuroimaging Analysis Center
Cantonal Hospital of St. Gallen
Central Texas Neurology Consultants
Fédération Hospitalo-Universitaire NEUROGENYCS
German Federal Ministry of Education and Research
Institut d'Investigacions Biomèdiques August Pi i Sunyer
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
National Multiple Sclerosis Society
Novo Cellular Medicine Institute LLP
Presbyterian/St. Luke's Medical Center, Denver
State University of New York, Buffalo
The University of Texas, Dallas
Organization Involved with Phase 1 Indications (32)
Organization Involved with Other Experimental Indications (3)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.